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Abstract 
Acute myocardial infarction is a leading cause of morbidity and mortality in the world. 
Reperfusion strategies are the current standard therapy for acute myocardial infarction 
(Neri, 2017). Most clinicians assume that ischemic injury terminates with return of 
spontaneous circulation (ROSC). However, according to Ibáñez 2015, damage inflicted 
on the myocardium during acute myocardial infarction is the result of two processes: 
ischemia and subsequent reperfusion (Ibáñez, 2015). The purpose of the poster is to 
inform clinicians regarding the process of ischemic injury, before and after reperfusion. 
Mitochondrial permeability transition pore (MPTP) is a large mega channel that opens 
due to increased Ca++, inorganic phosphate, or Reactive Oxygen Species (ROS), all of 
which are present in reperfusion. Opening of MPTP results in mitochondrial swelling and 
ultimately lead to rupture of the outer membrane. (Ibáñez, 2015). Reperfusion also 
triggers a complex inflammatory reaction accompanied by cytokine release and 
inflammatory leukocyte infiltration. This contributes to edema, phagocytosis, proteolysis, 
apoptosis, and collagen deposition (Jiaqi, 2016). Pharmacological interventions have 
proven to be effective in reducing reperfusion injury: Cyclosporine-A inhibits opening of 
MPTP, Metoprolol influences circulating neutrophils and platelets, and Glycoprotein 
IIb/IIIa inhibitors reduce thrombosis (Ibáñez, 2015). The “lethal reperfusion injury”, is 
currently accepted to significantly contribute to the final infarct size, and of late has 
become the topic of intensive research. There has been an increasing interest from basic 
and clinical researchers in identifying novel therapeutic strategies to attenuate lethal 
reperfusion injury and opportunities to translate these strategies into improved patient 
care (Duicu, 2013).
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